Pages that link to "Q37426527"

The following pages link to Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients (Q37426527):

Displaying 44 items.

• Treatment of chronic hepatitis C with direct-acting antivirals: The role of resistance (Q26740219) (← links)
• Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical Implications (Q26777408) (← links)
• Era of direct acting antivirals in chronic hepatitis C: Who will benefit? (Q26777506) (← links)
• HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy (Q26782405) (← links)
• Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance (Q26783056) (← links)
• Mouse Systems to Model Hepatitis C Virus Treatment and Associated Resistance (Q27469038) (← links)
• State of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and Immunization (Q28079102) (← links)
• Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control (Q28082128) (← links)
• Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay (Q28548426) (← links)
• High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods (Q28652352) (← links)
• Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data (Q31042796) (← links)
• Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China (Q33672648) (← links)
• Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. (Q35154587) (← links)
• Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia (Q35735285) (← links)
• Comprehensive Screening for Naturally Occurring Hepatitis C Virus Resistance to Direct-Acting Antivirals in the NS3, NS5A, and NS5B Genes in Worldwide Isolates of Viral Genotypes 1 to 6 (Q35917596) (← links)
• Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study (Q36100521) (← links)
• Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients (Q36182240) (← links)
• Analysis of Naturally Occurring Resistant Mutations to Hepatitis C Virus NS3 Protease Inhibitors: A Preliminary Study in South of Iran (Q36278496) (← links)
• Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naïve patients with chronic hepatitis C. (Q36292486) (← links)
• High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study (Q36651317) (← links)
• New treatments for chronic hepatitis C: an overview for paediatricians (Q38282842) (← links)
• Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals (Q38779980) (← links)
• Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. (Q38888859) (← links)
• Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden (Q39020651) (← links)
• Assessment of a Novel Automatic Real-Time PCR Assay on the Cobas 4800 Analyzer as a Screening Platform for Hepatitis C Virus Genotyping in Clinical Practice: Comparison with Massive Sequencing. (Q40419604) (← links)
• Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. (Q40784280) (← links)
• Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C (Q41521289) (← links)
• Use of simeprevir following pre-emptive pegylated interferon/ribavirin treatment for recurrent hepatitis C in living donor liver transplant recipients: a 12-week pilot study (Q42183060) (← links)
• Antiviral treatment of hepatitis C. (Q42207125) (← links)
• Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients. (Q44104489) (← links)
• Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China. (Q45324124) (← links)
• Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil. (Q45324912) (← links)
• Baseline and Breakthrough Resistance Mutations in HCV Patients Failing DAAs (Q47121746) (← links)
• Analysis of naturally occurring resistance-associated variants to NS3/4A protein inhibitors, NS5A protein inhibitors and NS5B polymerase inhibitors in patients with chronic hepatitis C. (Q47314419) (← links)
• Prevalence of NS5B resistance-associated variants in treatment-naïve Asian patients with chronic hepatitis C. (Q47397635) (← links)
• Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy. (Q55379857) (← links)
• Hepatitis C resistance to NS5A inhibitors: Is it going to be a problem? (Q57491238) (← links)
• Prevalence of hepatitis C virus NS5A resistance-associated substitutions in chronic infection with genotype 1: A pooled analysis based on deposited sequences in GenBank (Q58564271) (← links)
• Pretreatment Hepatitis C Virus NS5A/NS5B Resistance-Associated Substitutions in Genotype 1 Uruguayan Infected Patients (Q58780610) (← links)
• Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus (Q59126211) (← links)
• Prevalence and Factors Related to Natural Resistance-Associated Substitutions to Direct-Acting Antivirals in Patients with Genotype 1 Hepatitis C Virus Infection (Q61816060) (← links)
• Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes (Q64064438) (← links)
• Computational analysis of naturally occurring resistance-associated substitutions in genes NS3, NS5A, and NS5B among 86 subtypes of hepatitis C virus worldwide (Q90398259) (← links)
• The Investigation of Drug Resistance Substitutions in NS3 Protease Sequence of Hepatitis C Virus from Non-Responder Patients (Q92876947) (← links)